<DOC>
	<DOC>NCT00395772</DOC>
	<brief_summary>The purpose of this study is to determine the optimal dose of BAY 59-7939 and to compare the safety and effectiveness of this new drug with the standard way of treatment of deep vein thrombosis (heparin infusion plus one of the vitamin K antagonists), taking into account new events of thrombosis and pulmonary embolism and bleeding risk.</brief_summary>
	<brief_title>Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis</brief_title>
	<detailed_description>Within the U.S., Johnson &amp; Johnson is sponsor.</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Factor Xa Inhibitors</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Confirmed acute symptomatic DVT, i.e. proximal or extensive calfvein thrombosis involving at least the upper third part of the calf veins, without concomitant symptomatic PE Written informed consent Legal lower age limitations (country specific) Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT Other indication for VKA than PE/DVT More than 36 hours prerandomization treatment with therapeutic dosages of (LMW) heparin or more than a single dose of VKA prior to randomization Participation in another pharmacotherapeutic study within the prior 30 days Creatinine clearance &lt; 30 mL/min, impaired liver function (transaminases &gt; 2 x ULN), or bacterial endocarditis Life expectancy &lt; 3 months Active bleeding or high risk for bleeding contraindicating treatment with (LMW) heparin Uncontrolled hypertension: systolic blood pressure &gt; 200 mmHg and diastolic blood pressure &gt; 110 mmHg Pregnancy or childbearing potential without proper contraceptive measures Any other contraindication listed in the labeling of warfarin, acenocoumarol, phenprocoumon, fluindione, UFH, enoxaparin, or tinzaparin Systemic treatment with azole compounds or other strong CYP3A4 inhibitors (e.g. ketoconazole, fluconazol, itraconazole, HIV protease inhibitors) within 4 days prior to randomization and during the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Treatment of venous thromboembolism</keyword>
</DOC>